Reportlinker Adds The Women's Health Market Outlook to 2015

Dec 21, 2010, 11:22 ET from Reportlinker

NEW YORK, Dec. 21, 2010 /PRNewswire/ -- announces that a new market research report is available in its catalogue:

The Women's Health Market Outlook to 2015's-Health-Market-Outlook-to-2015.html

The global women's health market is increasingly competitive with, very few new active substances in the pipeline with the majority of research activity focuses on development of 'me-too' products, combinations and advanced re-formulations. The Women's Health Market Outlook to 2015 provides comprehensive coverage of the global women's health market, incorporating an overview of key diseases specific to women and a detailed epidemiological analysis. It makes a wide-ranging analysis of both currently marketed products and those in the product pipeline and gives an assessment of the leading players in the market.

Scope of this research

  • Understand how recent events are affecting the performance of major products, and how their marketers are confronting competitive market changes.
  • Compare the franchises of the leading companies in global women's health market, and understand how the market share of these companies will change.
  • Assess key pipeline products by indication, ongoing trials, recent product launches and key developments in R&D.
  • Identify the challenges confronted by leading players, and understand how recent events will impact the performance of leading products.
  • Access forecasts of the leading marketed and pipeline products through to 2015.

Research and analysis Highlights

The global women's health market was valued at $20.4bn at a Y-o-Y growth of 1%, the US dominated this market. Collectively, the top five EU markets represented the second largest women's health market with 2009 sales of $3.5bn and a market share of 17.3%.

Hormonal contraceptives with 2009 sales of $9bn represented 44.3% of the market and remained the major therapeutic class in the women's health market. Bayer's Yaz and Yasmin (drospirenone + ethinyl estradiol) were the largest selling drugs in this category accounting for a market share of 24.3%.

The top 10 generic players in the global women's health market represented 68.3% of the total generic market in 2009. J&J followed by Ferring remained the market leaders in the generic women's health market.

Key reasons to purchase this research

  • What will be the major growth indications and the accompanying growth drivers in the women's health market over the next 6 years?
  • Which companies led the women's health market in 2009?
  • Which products will be the future growth drivers for the women's health market?
  • Which therapeutic categories are forecast to have the highest levels of commercial potential over the period 2009–15?
  • Which companies are best positioned to succeed in the women's health market over the period 2009–15?

To order this report:

: The Women's Health Market Outlook to 2015

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!


Nicolas Bombourg



US: (805)652-2626

Intl: +1 805-652-2626

SOURCE Reportlinker